Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison
Abstract Background: Psoriasis is a chronic inflammatory skin disease with a genetic predisposition and autoimmune component, often treated with immunomodulators such as biologic therapies. Objectives: In this study, the authors evaluated the effectiveness and safety of two of these over a 52-week...
Saved in:
| Main Authors: | Leyla Baykal Selçuk, Hande Ermiş Akkuş, Burak Akşan, Deniz Aksu Arıca |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Dermatologia
2025-04-01
|
| Series: | Anais Brasileiros de Dermatologia |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962025000200305&lng=en&tlng=en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe
by: S. Ständer, et al.
Published: (2025-12-01) -
Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series
by: Andrea D'Arino, et al.
Published: (2025-07-01) -
Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study
by: Luciano Ibba, et al.
Published: (2024-12-01) -
Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil
by: Tania F. Cestari, et al.
Published: (2025-04-01) -
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
by: Richard B. Warren, et al.
Published: (2024-11-01)